ThinkGenetic Declared a Top Digital Health Startup

Share Article

ThinkGenetic pairs with Shire Plc and Massachusetts eHealth Institute (MeHI) to support development of new artificial intelligence diagnostic aid as part of PULSE@MassChallenge program.

News Image
“We are incredibly excited to know we have supporters in the Massachusetts community who not only believe in what we are trying to achieve, but are willing to champion our mission and accelerate our development." - Dave Jacob, Co-Founder and CEO, ThinkGenetic.

MassChallenge, a global network of startup accelerators, announced that ThinkGenetic is one of 32 top digital health startups joining the 2018 PULSE@MassChallenge cohort. Selected from more than 500 worldwide applicants, ThinkGenetic is amongst the most innovative technologies advancing healthcare and improving patient wellbeing.

“ThinkGenetic is honored to have been chosen for participation,” explains ThinkGenetic Co-Founder and CEO, Dave Jacob. “We are incredibly excited to know we have supporters in the Massachusetts community who not only believe in what we are trying to achieve, but are willing to champion our mission and accelerate our development.”

Beginning this month, ThinkGenetic has access to strategic partnerships, expert mentorship, tailored curriculum, co-working space, and the opportunity to apply for shares of $50,000 in need-based scholarships – all at zero cost and for zero equity. At the culmination of the program, ThinkGenetic will be eligible to compete for shares of $200,000 in cash prizes. To date, startups that have participated in PULSE@MassChallenge have experienced incredible growth, having raised more than $52M in funding, generated more than $13M in revenue, and grown their employee headcount by over 22 percent to date.

In addition, ThinkGenetic has been paired up with interested organizations who will help the company expand its reach and patient connections.

ThinkGenetic has two dedicated champions: Shire Plc(Shire) and Massachusetts eHealth Institute (MeHI).

Shire, the global leader in serving patients with rare diseases, will work with ThinkGenetic to determine the ability of its new artificial intelligence-driven diagnostic aid to help find patients with rare genetic diseases. There are more than 7,000 known rare diseases affecting an estimated 350 million people worldwide. Patients commonly experience delays to an accurate diagnosis, which can lead to serious consequences for their health and the wider healthcare systems. Shire feels a strong sense of urgency to address the unmet medical needs of those struggling with a rare disease and actively seeks innovative solutions, like those ThinkGenetic is developing, to help improve the lives of rare disease patients and those who care for them.

MeHI will help ThinkGenetic engage with appropriate state and industry stakeholders across the Commonwealth of Massachusetts.

Launched as a strategic component of the Massachusetts Digital Health Initiative, a statewide public-private partnership, PULSE@MassChallenge accelerates the impact of digital health startups around the world. Through rigorous matchmaking, PULSE@MassChallenge’s second cohort was selected by an impressive pool of institutions, providers, and payors ​looking to form unique partnerships with digital health startups. ​These Champions will​ support entrepreneurs throughout the program by facilitating key advisor introductions, pilots, research, and even investment opportunities.

To learn more about the PULSE@MassChallenge visit:

# # #

About ThinkGenetic, Inc. - ThinkGenetic locates individuals with diagnosed and undiagnosed genetic diseases using artificial intelligence (AI) solutions. Co-founded by a patient advocate and a genetic counselor, we know firsthand that people can wait a long time to receive a genetic diagnosis. People also have the power within themselves to shorten this diagnostic odyssey. ThinkGenetic helps individuals harness this power by offering trustworthy information to guide them to the help they need, faster. Undiagnosed individuals, patients, and families are our focus and this sets us apart. For more information, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ruth O'Keefe
Follow >
since: 01/2016
Like >

Follow us on
Visit website